The latest verified performance data from Nagarro comes from FY2025, where revenue reached €999.3 million-representing 2.8% nominal growth and 6.1% growth in constant currency terms from €972.0 million in 2024. Gross margin expanded meaningfully to 32.2% from 30.4% the prior year, while Adjusted EBITDA margin came in at 13.8%, within the company's revised guidance range of 13.5% to 14.5% but down from 15.2% in 2024.
For FY2026, management has guided to revenue between €1,000 million and €1,060 million at current FX rates implying roughly 5% growth at the midpoint, with Adjusted EBITDA margin targeted at 14.5% to 15.5%.
The 6.5% YoY revenue growth figure in constant currency for Q1 2026 sits above the FY2025 constant currency pace of 6.1%, suggesting the quarter maintained or slightly accelerated the underlying growth trajectory despite the challenging demand environment management has cited. However, the nominal growth rate would be lower given current FX headwinds.
The margin profile presents a more nuanced picture. The 32.2% gross margin in FY2025 showed meaningful year-over-year improvement, but Adjusted EBITDA margin contracted to 13.8% from 15.2%-a decline driven by both the €15.5 million unrealized FX loss on intra-group loans and the €12.4 million one-time expense related to India's new labor codes both of which impacted the bottom line.
For Q1 2026 to be considered "priced for perfection," the market would need to be expecting not just revenue growth but also margin stabilization or expansion. The FY2025 EBITDA compression-despite gross margin improvement-suggests operational leverage remains under pressure, which could be a key point of scrutiny if Q1 2026 delivers strong top-line growth but continued margin headwinds.
Growth Quality and Sustainability Analysis
The FY2025 numbers reveal a telling divergence: gross profit grew 8.6% to €321.3 million, outpacing revenue growth and pushing gross margin up 180 basis points to 32.2% from €295.8 million in 2024. This suggests pricing power is holding and the mix is shifting toward higher-value work. Yet Adjusted EBITDA fell 6.3% to €138.2 million, compressing the margin to 13.8% from 15.2% a 140bp contraction.
The gap between gross profit strength and EBITDA weakness is where the real story lives. Two items explain most of the disconnect. First, a €12.4 million one-off expense from India's new labor codes increased defined benefit obligations related to past service costs. Second, and more materially, an unrealized FX loss of €15.5 million on intra-group loans hit EBITDA directly-and notably, this was not adjusted out in the reported figure impacting the bottom line. Together, these items account for roughly €28 million in headwind, or about 2.8 percentage points of revenue.
Strip out those items and the picture shifts. Adjusted for FX alone, management noted Adjusted EBITDA would have been approximately €153.7 million, placing it toward the higher end of the guided margin range towards the higher end of our guided Adjusted EBITDA margin range. The question for investors is whether the market is treating the 13.8% margin as structural or transitory.
Historically, Nagarro has delivered strong returns-ROE of 25.5% with net margins around 4% based on historical performance. The current EBITDA compression, if persistent, would pressure that return profile. The gross margin expansion is encouraging; it shows the underlying business model retains leverage. But until the one-offs fade and the FX environment stabilizes, the sustainability of margin recovery remains unproven.
For a stock potentially priced for perfection, the risk is asymmetric: gross margin trends are positive, but EBITDA has yet to demonstrate a clear recovery path. The market will be watching whether Q1 2026 shows the margin contraction abating-or whether the one-offs are merely the visible tip of a broader operational leverage challenge.
Valuation and Market Expectations
The FY2026 guidance of €1,000 million to €1,060 million implies revenue growth of roughly 0% to 6% at the extremes, with the midpoint around 3% at current FX rates. That is notably more cautious than the historical revenue growth rate of 15.7% per year that Nagarro has delivered on average. The market, however, may already be pricing in this caution-or perhaps something more.
The EBITDA margin guidance tells a different story. Management is targeting 14.5% to 15.5% for FY2026, a meaningful recovery from the 13.8% actually achieved in FY2025 which was impacted by FX losses and one-off items. This implies confidence that the margin compression was largely transitory. If true, the stock could be positioned for a double-digit earnings expansion as margins normalize. The question is whether investors believe the recovery is achievable-or whether they are discounting the guidance as management optimism.
The first-ever dividend of €1.00 per share proposed by the Management and Supervisory Boards is a meaningful signal. It demonstrates confidence in cash generation and capital return capacity. But it also raises the question: is this a genuine commitment to shareholder returns, or a one-time gesture to reset the narrative after the fraud allegations? The independent investigation's conclusion that there was no evidence of fraud or misconduct removes a significant overhang, but the market's reaction to that news will tell us whether the stigma has already been priced out.
Here's the tension: historical ROE of 25.5% and net margins around 4% suggest a highly efficient operation, yet the current EBITDA margin of 13.8%-and the guidance toward 14.5-15.5%-implies a recovery path that hasn't been fully demonstrated. The gross margin expansion to 32.2% in FY2025 is encouraging, but EBITDA has yet to show a clear recovery. For a stock potentially priced for perfection, the risk is asymmetric: the upside requires margin recovery to materialize, while the downside is exposed if the one-offs were merely the visible tip of a broader operational leverage challenge.
The cautious revenue guidance, combined with the margin recovery target, suggests management is playing it safe on top-line growth while betting on operational leverage to drive earnings. If the market has already priced in the fraud overhang and is expecting the margin recovery, then the stock could be vulnerable to any disappointment. If, however, the market remains skeptical of the margin story, there may be upside as the FY2026 numbers unfold. The key is whether the 6.5% Q1 2026 growth (in constant currency) is sustained-and whether the margin contraction abates.
Catalysts and Risks to Watch
The stock now hinges on a simple question: can Nagarro deliver on the margin recovery story while sustaining its 6.5% growth trajectory? The answer will determine whether the current valuation is justified or if asymmetric risks lurk beneath the surface.
Upside scenario centers on operating leverage materializing. Gross margin already expanded to 32.2% in FY2025, and management is guiding toward 32% again for FY2026 at current FX rates. If the company can stabilize the EBITDA margin at the higher end of its 14.5% to 15.5% guidance range-particularly if the €15.5 million FX loss and €12.4 million India labor code expense prove truly transitory-the earnings power could expand double-digit. That recovery, combined with the first-ever €1.00 dividend, would